Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics Inc
(NQ:
ALGS
)
10.19
+0.27 (+2.72%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aligos Therapeutics Inc
< Previous
1
2
3
Next >
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 10, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
February 08, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
January 05, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
December 14, 2022
Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
December 08, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
November 04, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
November 04, 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
November 02, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
October 21, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
October 19, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
October 18, 2022
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
October 14, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
September 28, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
July 27, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
NASDAQ: ALGS Investor Notice: Investigation over Potential Wrongdoing at Aligos Therapeutics, Inc.
April 15, 2022
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation on behalf of investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential wrongdoing at Aligos Therapeutics, Inc. was...
Via
SBWire
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
January 28, 2022
From
Robbins LLP
Via
Business Wire
NASDAQ: ALGS Shareholder Notice: Investigation over Potential Securities Laws Violations by Aligos Therapeutics, Inc.
January 24, 2022
San Diego, CA -- (SBWIRE) -- 01/24/2022 -- An investigation for investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential securities laws violations by Aligos Therapeutics, Inc. was...
Via
SBWire
ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders and Encourages Investors to Contact the Firm
January 21, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
January 20, 2022
From
Robbins LLP
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.